Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered by Pengfei Chen, Kun Li, Jinwei Chen, He Hei, Jiaxin Geng, Nannan Huang, Mengyu Lei, Huijie Jia, Jianzhuang Ren, Chenwang Jin

Subjects: Get full text

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma by Saffron E. Summers, Saffron E. Summers, Vehid Salih, Andrew D. Foey

Subjects: Get full text

Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity by Yujia Zhao, Dan Liu, Wenguang Yang, Wangxiao He, Jin Yan, Leiqing Yao

Subjects: Get full text

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis by Preston Ngo, Wendy A. Cooper, Stephen Wade, Kwun M. Fong, Karen Canfell, Deme Karikios, Marianne Weber

Subjects: “…PD-L1…”
Get full text

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma by Mengdi Fu, Huimei Zhou, Jiaxin Yang, Dongyan Cao, Zhen Yuan

Subjects: Get full text

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study by Haiqing Zhao, Wei Zhang, Yuting Lu, Yin Dong, Zhihao He, Hongchao Zhen, Qin Li

Subjects: Get full text

Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico by Waqas Safir, Arif Malik, Arif Malik, Haleema Saadia, Ayesha Zahid, Jinyao Li

Subjects: Get full text

NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma by Chao-Yan Yao, Hang-Tian Tao, Jin-Jin He, Feng-Yi Zhu, Cui-Qing Xie, Yu-Na Cheng, Ji-Qin Li, Zhuang-Zhuang Liu, Chun-Yu Hou, Xue-Li Liu, Yong-Li Fan, Dong Fang, Xin-Rui Lv

Subjects: Get full text

Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis by Minjing Zou, Amal Qattan, Monther Al-Alwan, Hazem Ghebeh, Naif Binjumah, Latifa Al-Haj, Khalid S. A. Khabar, Abdulmohsen Altaweel, Falah Almohanna, Abdullah M. Assiri, Abdelilah Aboussekhra, Ali S. Alzahrani, Ali S. Alzahrani, Yufei Shi

Subjects: “…CD274 (PD-L1)…”
Get full text

Prognostic value of tumor‐infiltrating lymphocytes and PD‐L1 expression in esophageal squamous cell carcinoma by Jie Hu, Takeshi Toyozumi, Kentaro Murakami, Satoshi Endo, Yasunori Matsumoto, Ryota Otsuka, Tadashi Shiraishi, Shinichiro Iida, Hiroki Morishita, Tenshi Makiyama, Yuri Nishioka, Masaya Uesato, Koichi Hayano, Akira Nakano, Hisahiro Matsubara

Subjects: Get full text

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report by Jingjing Chai, Jiaqi Lv, Jian Xiong, Xiuwen Chen, Senyuan Luo, Zhiguo Luo, Zhiguo Luo, Ming Luo

Subjects: Get full text

The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients by Li Wang, Yingjun Kong, Yao Zhang, Chuanyong Mu

Subjects: Get full text

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients by Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida

Subjects: Get full text

Programmed Cell Death Ligand 1 (PD-L1) and major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in triple-Negative Breast Ca... by Kaewkedsri P, Intarawichian P, Jessadapattarakul S, Kunprom W, Koonmee S, Thanee M, Somintara O, Wongbuddha A, Chadbunchachai P, Nawapun S, Aphivatanasiri C

Subjects: Get full text